1 9 2 0 3 1 at the time of bleomycin exposure decreases terminal UPR signaling and prevents lung fibrosis.
Introduction 4 0
The unfolded protein response (UPR) is a conserved signaling pathway that is activated Page 5 we isolated primary type II alveolar epithelial cells from mouse lungs by dissociation and cell 1 0 5 sorting as previously described [28, 29] . As in the MLE12 cell lines, tunicamycin induced 1 0 6 apoptosis in primary type II alveolar epithelial cells in an IRE1α-dependent manner ( Fig 1C) . Ethidium bromide-stained agarose gel of XBP1 cDNA amplicons. Mouse Lung Epithelial 1 1 0 (MLE12) cells were exposed to Tunicamycin (Tun) 2.5 μ g/ml and indicated To evaluate the role of IRE1α in vivo, we turned to the bleomycin model of pulmonary Page 6 ( Fig 2A) . This wave of ER stress and terminal UPR activation peaks at day 8 and remains 1 3 0 elevated through day 26 (Fig 2A) . This initial, early wave of terminal UPR signaling is followed 1 3 1 by overt fibrosis; mRNA levels of collagen 1A1 and fibronectin rise at day 8 and peak on day 14, 1 3 2 followed by waning levels over the following two weeks ( Fig 2B) . CHOP from mice at 0, 2, 8, 14, 20, or 26 days after a single exposure to bleomycin. Quantitative PCR for collagen 1A1 mRNA and fibronectin mRNA from at 0, 2, 8, 14, 20, 1 3 9 or 26 days after a single exposure to bleomycin. Each mouse is represented by a dot, 1 4 0 and whiskers denote group mean +/-SEM. P values: *<0.05, **<0.01, ***<0.001. tool compound for in vivo use in part due to its high IC50 of 9.9 µM and because of poor 1 4 7 solubility (Selleckchem manufacturer datasheet). Therefore, for in vivo experiments we used 1 4 8 KIRA7, an imidazopyrazine compound that binds the IRE1α kinase to allosterically inhibit its 1 4 9
RNase activity ( Fig 3A) . KIRA7, also referred to a Compound 13 [25] , is a modification of our properties. Mice were exposed to a single dose of intranasal bleomycin (1.5 units/kg), then 1 5 2 treated with either KIRA7 (5 mg/kg/day i.p.) or an equivalent volume of vehicle, starting on the collected on day 14 for analysis ( Fig 3B) . (B) Schematic of the KIRA7 prevention regimen. Mice were exposed to saline or Although day 14 is after peak expression of markers of the terminal UPR (Fig 2A) , 1 7 1 protein levels of spliced XBP1 and ATF4 remain significantly elevated in bleomycin-exposed 1 7 2 mice, compared to saline-exposed controls ( Fig 3C) . Treatment of bleomycin-exposed mice with 1 7 3 KIRA7 resulted in decreased spliced XBP1 and ATF4, compared to bleomycin exposed mice 1 7 4 treated with vehicle ( Fig 3C) . Likewise, mRNA levels of BiP and CHOP are significantly elevated 1 7 5 after bleomycin exposure, and treatment of bleomycin-exposed mice with KIRA7 decreased 1 7 6 these levels ( Fig 3D, p<0 .05).
Page 8
These decreases in markers of the terminal UPR were accompanied by significant 1 7 8 improvements in bleomycin-induced fibrosis. Histologically, bleomycin exposure induced 1 7 9 destruction of alveoli, cell infiltration, and architectural distortion in the lung. By contrast, alveolar 1 8 0 architecture was largely preserved in lungs of mice exposed to bleomycin and treated with 1 8 1 KIRA7 ( Fig 3E) . Bleomycin exposure induced fibrosis as measured by lung weight and total 1 8 2 hydroxyproline, and both were significantly decreased with KIRA7 treatment (p<0.05). Consistent with these decreases, mRNA levels of collagen 1A1 and fibronectin were both 1 8 4 significantly decreased by KIRA7 treatment (p<0.001 and p<0.01, respectively). Administration of KIRA7 protects against fibrosis during the initial injury after bleomycin, 1 8 8 which is also when ER stress and terminal UPR markers are at their peak (Fig 2A) . We 1 8 9 wondered whether KIRA7 might even protect against fibrosis when administered later (i.e., in a 1 9 0 therapeutic rather than a prophylactic regimen), two weeks after initial injury, when terminal 1 9 1 UPR markers are still elevated albeit to a lesser degree (Fig 2A) . In addition, early injury in the 1 9 2 first week after bleomycin administration is characterized by neutrophilic and lymphocytic 1 9 3 inflammatory infiltration, which is not thought to be characteristic of human IPF [30] . The initial 1 9 4 alveolitis clears around day 7, followed by fibroblast proliferation and matrix deposition; fibrosis 1 9 5 is typically established by day 14 ( Fig 2B) [30]. Thus, administration of KIRA7 after day 14 may 1 9 6 have greater relevance to human IPF, where fibrosis may progress for years before the onset of 1 9 7 clinical symptoms and diagnosis. As before, mice were exposed to a single dose of intranasal bleomycin (1.5 units/kg). Beginning on day 14, mice were treated with either KIRA7 (5 mg/kg/day i.p.) or an equivalent 2 0 0 volume of vehicle; injections were continued daily until day 28. Whole lung protein and RNA 2 0 1 were collected on day 28 for analysis ( Fig 4A) . As expected, bleomycin-exposed mice had 2 0 2 increased levels of spliced XBP1, ATF4, and CHOP protein at day 28 ( Fig 4B) . Treatment of 2 0 3 Page 9 bleomycin-exposed mice was associated with decreases in levels of these proteins ( Fig 4B) . KIRA7 also blunted bleomycin-induced increases in lung weight (p<0.001) and hydroxyproline 2 0 5 (p<0.05) ( Fig 4C) . At day 28, mRNA levels of collagen 1A1 and fibronectin remain elevated 2 0 6 above baseline, albeit at lower levels compared to day 28 ( Fig 4C) , consistent with the 2 0 7 observation that synthesis of collagen and fibronectin mRNA peaks at day 14 and wanes 2 0 8 thereafter ( Fig 2B) . Nonetheless, administration of KIRA7 decreased mRNA levels of collagen 2 0 9 1A1 (p<0.05) and fibronectin (p<0.05). weight, hydroxyproline content, collagen 1A1 mRNA, and fibronectin mRNA) from mice 2 1 8 exposed exposed to saline or bleomycin, and treated with KIRA7 according to the 2 1 9 reversal regimen. Each mouse is represented by a dot, and whiskers denote group Page 10 nM, data not shown). Consistent with this, KIRA8 has higher potency than KIRA7 in inhibiting 2 2 9 XBP1 splicing in the alveolar epithelial cell line MLE12 ( Fig 5B) . KIRA8 reversal regimen. Mice were exposed to saline or bleomycin once, then treated mRNA, and fibronectin mRNA) from mice exposed exposed to saline or bleomycin, and We evaluated the ability of KIRA8 to mitigate established fibrosis. Mice were exposed to 2 4 7 a single dose of intranasal bleomycin (1.5 units/kg), and treated with either KIRA8 (50 2 4 8 mg/kg/day i.p.) or an equivalent volume of vehicle starting at day 14 and continuing daily until 2 4 9 day 28. Whole lung protein and RNA were collected on day 28 for analysis ( Fig 5C) . KIRA8 2 5 0 treated mice had lower levels of spliced XBP1, ATF4, and CHOP protein ( Fig 5D) . As before, Page 11 hydroxyproline (p<0.01), and decreased mRNA expression of collagen 1A1 (p<0.001) and 2 5 3 fibronectin (p<0.05) ( Fig 5E) . We have shown that ER stress induces apoptosis in a mouse alveolar epithelial cell line 2 5 7 and mouse primary type II alveolar epithelial cells, and that inhibiting the IRE1α RNase proposed that various insults to the alveolar epithelium lead ultimately to terminal UPR signaling 2 7 1 [18] [19] [20] [21] . In both cases, modulating the activity of IRE1α would be predicted to blunt terminal 2 7 2 UPR signaling, promote alveolar epithelial cell survival, and thus mitigate ongoing fibrosis. Another intriguing possibility is that IRE1α activity may also contribute directly to [33]. This finding may help explain why late administration of KIRA7 and KIRA8, two weeks after 2 7 7 bleomycin injury, can promote the reversal of established fibrosis (Fig 4 and Fig 5) . The possible Page 12 roles of IRE1α in epithelial cells and fibroblasts are not mutually exclusive, and extensive work 2 7 9 outside the scope of this study is needed to elucidate the precise role(s) of IRE1α in the injured 2 8 0 lung.
8 1
The anti-fibrotic activity of KIRA7 and KIRA8 even when administered late is particularly 2 8 2 important when considering potential therapeutic avenues in human disease. In IPF, subclinical 2 8 3 fibrosis starts years before patients are symptomatic enough to come to medical attention, and 2 8 4 even then diagnosis is often delayed [34, 35] . These results suggest that targeting IRE1α may 2 8 5 possibly be effective even when fibrosis is advanced. In addition, severe pathological lung 2 8 6 fibrosis, evidenced by the "usual interstitial pneumonia" pattern radiographically and 2 8 7 histologically, is the final common endpoint to chronic injury in non-IPF interstitial lung diseases, pneumonitis, and asbestosis [36] . Targeting IRE1α holds therapeutic promise to the extent that 2 9 0 ER stress is important to the primary pathology and initial injury in these diseases, as has been 2 9 1 suggested in some forms of genetic autoimmune-associated interstitial lung disease [37] and 2 9 2 asbestosis [38]. To the extent that targeting IRE1α might mitigate pathological fibroblast activity, 2 9 3 targeting IRE1α may be useful even in cases where ER stress is not part of the primary 2 9 4 pathology.
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In summary, we have shown that intra-airway bleomycin, the most commonly used 2 9 6 murine model of pulmonary fibrosis, induces the unfolded protein response and that this 2 9 7 response precedes the development of pulmonary fibrosis. Furthermore, two chemically distinct 2 9 8 small molecules that inhibit IRE1α kinase and attenuate its RNase activity (KIRAs) are effective 2 9 9 in preventing and reversing bleomycin induced pulmonary fibrosis. This work lays the 3 0 0 groundwork for developing KIRAs as novel therapeutics for IPF and other interstitial lung RNA was isolated from whole cells or mouse tissues and reverse transcribed as above were counted using a Becton Dickinson LSRII flow cytometer. 
